On October 10, 2018, President Donald Trump signed into law the “Know the Lowest Price Act” and the “Patients’ Right to Know Drug Prices Act,” which aim to improve consumer access to drug price information by banning gag clauses. The Trump administration previously announced its intention to enact this legislation in its May 2018 Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs and will likely point to these new federal laws as affirmation of its commitment to drug pricing reform that favors patients and consumers.
These bills—one of which applies to ...
One of the most discussed aspects of healthcare has to be how to balance cost, quality and access. This is especially true when it comes to the pharmaceutical industry, particularly with the rapid growth of and increased focus on highly effective, but highly expensive, specialty drugs. Discussions about these costs are no longer isolated to negotiations between pharmaceutical companies, PBMs and insurers; instead it appears that price and cost are on FDA's radar.
For example, the Oncologic Drugs Advisory Committee ("ODAC") hearing, earlier this month, was not only historic ...
Blog Editors
Recent Updates
- Exemptions from the Drug Supply Chain Security Act Enhanced Drug Distribution Security Requirements
- Investors, Researchers, and Business Leaders Take Note: $110M Awarded to Advance Women’s Health
- States Fill Gaps in Hospital Workplace Violence Laws—Requiring Law Enforcement Officers, Weapons Detection Screening Policies in Hospitals, and More
- Georgia & North Dakota: More State Judges Question the Constitutionality of Abortion Bans
- OCR Withdraws Appeal of District Court Order Declaring Unlawful and Vacating the “Proscribed Combination” Portion of Its HIPAA Online Tracking Technologies Guidance